Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-25T11:33:37.761Z Has data issue: false hasContentIssue false
  • English
  • Français

Analysis of Leishmania mimetic neoglycoproteins for the cutaneous leishmaniasis diagnosis

Published online by Cambridge University Press:  28 May 2018

Lígia Moraes Barizon de Souza ,
Vanete Thomaz Soccol ,
Ricardo Rasmussen Petterle ,
Michelle D. Bates  and
Paul A. Bates
Lígia Moraes Barizon de Souza
Affiliation:
Laboratory of Molecular Biology, Department of Bioprocess Engineering and Biotechnology, Universidade Federal do Paraná, Avenida Coronel Francisco Heráclito dos Santos, 210 – Usina Piloto B, Curitiba, Paraná 81531-970, Brazil
Vanete Thomaz Soccol
Affiliation:
Laboratory of Molecular Biology, Department of Bioprocess Engineering and Biotechnology, Universidade Federal do Paraná, Avenida Coronel Francisco Heráclito dos Santos, 210 – Usina Piloto B, Curitiba, Paraná 81531-970, Brazil
Ricardo Rasmussen Petterle
Affiliation:
Nucleus of Medical Education, Department of Community Health, Universidade Federal do Paraná, Rua Padre Camargo, 280 – 7th floor, Curitiba, Paraná 80060-240, Brazil
Michelle D. Bates
Affiliation:
Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, Lancashire, LA1 4YQ, UK
Paul A. Bates*
Affiliation:
Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, Lancashire, LA1 4YQ, UK
*
Author for correspondence: Paul A. Bates, E-mail: p.bates@lancaster.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Oligosaccharides are broadly present on Leishmania cell surfaces. They can be useful for the leishmaniases diagnosis and also helpful in identifying new cell markers for the disease. The disaccharide Galα1-3Galβ is the immunodominant saccharide in Leishmania cell surface and is the unique non-reducing terminal glycosphingolipids structure recognized by anti-α-Gal. This study describes an enzyme-linked immunosorbent assay (ELISA) used to measure serum levels of anti-α-galactosyl (α-Gal) antibodies in patients with cutaneous leishmaniasis (CL). Optimal ELISA conditions were established and two neoglycoproteins (NGP) containing the Galα1-3Gal terminal fraction (Galα1-3Galβ1-4GlcNAc-HAS and Galα1-3Gal-HAS) and one Galα1-3Gal NGP analogue (Galα1-3Galβ1-3GlcNAc-HAS) were used as antigens. Means of anti-α-Gal antibody titres of CL patients were significantly higher (P < 0.05) than the healthy individuals for all NGPs tested. Sensitivity and specificity of all NGPs ranged from 62.2 to 78.4% and 58.3 to 96.7%, respectively. In conclusion, the NGPs can be used for CL diagnosis.

Keywords

α-galactosylantigenELISAL. braziliensissaccharide
Type
Research Article
Information
Parasitology , Volume 145 , Issue 14 , December 2018 , pp. 1938 - 1948
Check for updates
Copyright
Copyright © Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Almeida, IC et al. (1994) Lytic anti-x-galactosyl antibodies from patients with chronic Chagas’ disease recognize novel 0-linked oligosaccharides on mucin-like glycosylphosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. Journal of Biochemistry 304, 793–802, PMID: 7818483Google Scholar
Al-Salem, WS et al. (2014) Detection of high levels of anti-α-galactosyl antibodies in sera of patients with Old World cutaneous leishmaniasis: a possible tool for diagnosis and biomarker for cure in an elimination setting. Parasitology 141, 1898–1903.Google Scholar
Alvar, J et al. (2012) The WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7(1), e35671.Google Scholar
Ashmus, RA et al. (2013) Potential use of synthetic α-galactosyl-containing glycotopes of the parasite Trypanosoma cruzi as diagnostic antigens for Chagas disease. Organic Biomolecular Chemistry 34, 5579–5583.Google Scholar
Ávila, JL and Rojas, M. (1990) A galactosyl(α1–3)mannose epitope on phospholipids of Leishmania mexicana and L. braziliensis is recognized by trypanosomatid-infected human sera. Journal of Clinical Microbiology 7, 1530–1537.Google Scholar
Ávila, JL, Rojas, M and Garcia, L (1988) Persistence of elevated levels of Galactosyl-α(1–3)Galactose antibodies in sera from patients cured of Visceral Leishmaniasis. Journal of Clinical Microbiology 9, 1842–1847.Google Scholar
Ávila, JL, Rojas, M and Galili, U (1989) Immunogenic Galα1-3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. Journal of Immunology 8, 2828–2834.Google Scholar
Ávila, JL, Rojas, M and Acosta, A (1991) Glycoinositol phospholipids from American Leishmania and Trypanosoma spp: partial characterization of the glycan cores and the human humoral immune response to them. Journal of Clinical Microbiology 10, 2305–2312.Google Scholar
Barreto-Bergter, E and Vermelho, AB (2010) Structures of glycolipids found in Trypanosomatids: contribution to parasite functions. The Open Parasitology Journal 4, 84–97.Google Scholar
Bhargava, P and Singh, R (2012) Developments in diagnosis and antileishmanial drugs. Interdisciplinary Perspectives on Infectious Diseases 2012, 1–13. doi: 10.55/2012/626838.Google Scholar
Bifeld, E and Clos, J (2015) The genetics of Leishmania virulence. Medical Microbiology and Immunology 204, 619–634.Google Scholar
Campos, MB et al. (2008) In vitro infectivity of species of Leishmania (Viannia) responsible for American cutaneous leishmaniasis. Parasitology Research 103, 771–776.Google Scholar
David, CV and Craft, N (2009) Cutaneous and mucocutaneous leishmaniasis. Dermatologic Therapy 22, 491–502.Google Scholar
De Vries, HJC, Reedijk, SH and Schallig, HDFH (2015) Cutaneous Leishmaniasis: recent developments in diagnosis and management. American Journal of Clinical Dermatology 16, 99–109.Google Scholar
Fernández-Tejada, A, Cañada, FJ and Jiménez-Barbero, J (2015) Recent developments in synthetic carbohydrate-based diagnostics, vaccines, and therapeutics. Chemistry 30, 10616–10628.Google Scholar
Galili, U (1989) Abnormal expression of α-Galactosyl epitopes in man: a trigger for autoimmune processes? The Lancet 8659, 358–361.Google Scholar
Galili, U (1993) Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Seminars in Immunopathology 15, 155–171, PMID: 7504839.Google Scholar
Galili, U (2013 a) Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology 1, 1–11.Google Scholar
Galili, U (2013 b) Α1,3Galactosyltransferase knockout pigs produce the natural anti-Gal antibody and simulate the evolutionary appearance of this antibody in primates. Xenotransplantation 5, 267–276.Google Scholar
Galili, U and Andrews, P (1995) Suppression of α-galactosyl epitopes synthesis and production of the natural anti-Gal antibody: a major evolutionary event in ancestral Old World primates. Journal for Human Evolution 5, 433–442.Google Scholar
Galili, U et al. (1984) A unique natural human IgG antibody with anti-α-galactosyl specificity. The Journal of Experimental Medicine 5, 1519–1531.Google Scholar
Galili, U et al. (1985) Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1-3)-linked galactose residues. The Journal of Experimental Medicine 2, 573–582.Google Scholar
Galili, U et al. (1987) Evolutionary relationship between the natural anti-Gal antibody and the Galα1-3Gal epitope in primates. Proceedings of the National Academy of Sciences of the United States of America 5, 1369–1373.Google Scholar
Galili, U et al. (1988) Man, Apes, and Old World Monkeys differ from other mammals in the expression of α-Galactosyl epitopes on nucleated cells. The Journal of Biological Chemistry 33, 17755–17762.Google Scholar
Georgiadou, SP, Makaritsis, KP and Dalekos, GN (2015) Leishmaniasis revisited: current aspects on epidemiology, diagnosis and treatment. Journal of Translational Internal Medicine 3(2), 43–50.Google Scholar
Goto, H and Lindoso, JAL (2012) Cutaneous and mucocutaneous leishmaniasis. Infectious Disease Clinics of North America 26, 293–307.Google Scholar
Handler, MZ et al. (2015) Cutaneous and mucocutaneous leishmaniasis: differential diagnosis, diagnosis, histopathology, and management. Journal of American Academy of Dermatology 73(6), 911–926.Google Scholar
Ilgoutz, SC and McConville, MJ (2001) Function and assembly of the L eishmania surface coat. International Journal for Parasitology 9, 899–908.Google Scholar
Macher, BA and Galili, U (2008) The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochimica et Biophysica Acta 2, 75–88.Google Scholar
Maia, Z et al. (2012) Comparative study of rK39 Leishmania antigen for serodiagnosis of visceral leishmaniasis: systematic review with meta-analysis. PLoS Neglected Tropical Disease 6(1), e1484.Google Scholar
McConville, MJ and Ferguson, MA (1993) The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes. Journal of Biochemistry 294, 305–324. PMC:1134455.Google Scholar
Mukhopadhyay, S, Bandyopadhyay, N and Mandal, C (2006) Glycobiology of Leishmania donovani. Indian Journal of Medical Research 3, 203–220.Google Scholar
Obukhova, P, Rieben, R and Bovin, N (2007) Normal human serum contains high levels of anti-Galα1-4GlcNAc antibodies. Xenotransplantation 6, 627–635.Google Scholar
Paiva-Cavalcanti, M et al. (2015) Leishmaniases diagnosis: an update on the use of immunological and molecular tools. Cell & Bioscience 5, 31.Google Scholar
Peacock, CS et al. (2007) Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nature Genetics 39(7), 839–847.Google Scholar
Rezvan, H (2014) Evaluation of different approaches in Leishmania diagnosis. International Journal of Advanced Biological and Biomedical Research 2(2), 238–261.Google Scholar
Robin, X et al. (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77. DOI: 10.1186/1471-2105-12-77.Google Scholar
Sánchez-Ovejero, C et al. (2016) Sensing parasites: proteomic and advanced bio-detection alternatives. Journal of Proteomics 136, 145–156.Google Scholar
Satapathy, AK and Ravindran, B (1999) Naturally occurring α-galactosyl antibodies in human sera display polyreactivity. Immunology Letters 3, 347–351.Google Scholar
Schocker, NS et al. (2016) Synthesis of Galα(1,3)Galβ(1,4)GlcNAcα-, Galβ(1,4)GlcNAcα- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease. Glycobiology 1, 39–50.Google Scholar
Van Der Auwera, G and Dujardin, JC (2015) Species typing in dermal leishmaniasis. Clinical Microbiology Reviews 28(2), 265–294.Google Scholar